C19H23NO4
Neat
329.4
beta-Naloxol; .BETA.-NALOXOL; QY92ZV4EHS; .BETA.-NALOXOL [MI]; N-ALLYL-14-HYDROXY-7, 8-DIHYDRONORISOMORPHINE; (5.ALPHA., 6.BETA.)-4, 5-EPOXY-17-(2-PROPEN-1-YL)MORPHINAN-3, 6, 14-TRIOL; MORPHINAN-3, 6, 14-TRIOL, 4, 5-EPOXY-17-(2-PROPEN-1-YL)-, (5.ALPHA., 6.BETA.)-; MORPHINAN-3, 6, 14-TRIOL, 4, 5-EPOXY-17-(2-PROPENYL)-, (5.ALPHA., 6.BETA.)-; RefChem:199853; (5ALPHA, 6BETA)-4, 5-EPOXY-17-(2-PROPEN-1-YL)MORPHINAN-3, 6, 14-TRIOL; MORPHINAN-3, 6, 14-TRIOL, 4, 5-EPOXY-17-(2-PROPEN-1-YL)-, (5ALPHA, 6BETA)-; MORPHINAN-3, 6, 14-TRIOL, 4, 5-EPOXY-17-(2-PROPENYL)-, (5ALPHA, 6BETA)-; 53154-12-4; DTXSID80201230; Naloxone Impurity 22; 6.BETA.-NALOXOL; SCHEMBL22224716; PD057723; (4R, 4aS, 7R, 7aR, 12bS)-3-allyl-1, 2, 3, 4, 5, 6, 7, 7a-octahydro-4aH-4, 12-methanobenzofuro[3, 2-e]isoquinoline-4a, 7 and 9-triol
(4R, 4aS, 7R, 7aR, 12bS)-3-prop-2-enyl-1, 2, 4, 5, 6, 7, 7a, 13-octahydro-4, 12-methanobenzofuro[3, 2-e]isoquinoline-4a, 7 and 9-triol
InChI=1S/C19H23NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,13-14,17,21-23H,1,5-10H2/t13-,14-,17+,18+,19-/m1/s1